Dobric, Aleksandar; De Luca, Simone N; Spencer, Sarah J; Bozinovski, Steven; Saling, Michael M; McDonald, Christine F; Vlahos, Ross

doi:10.1016/j.pharmthera.2021.108017

Author(s)

Dobric, Aleksandar

De Luca, Simone N

Spencer, Sarah J

Bozinovski, Steven

Saling, Michael M

McDonald, Christine F

Vlahos, Ross

Publication Date

2021-10-06

Abstract

Chronic obstructive pulmonary disease (COPD) is a major incurable global health burden and currently, the 3rd largest cause of death in the world with approximately 3.23 million deaths per year. Globally, the financial burden of COPD is approximately €82 billion per year and causes substantial morbidity and mortality. Importantly, much of the disease burden and health care utilisation in COPD is associated with the management of its comorbidities and viral and bacterial-induced acute exacerbations (AECOPD). Recent clinical studies have shown that cognitive dysfunction is present in up to 60% of people with COPD, with impairments in executive function, memory, and attention, impacting on important outcomes such as quality of life, hospitalisation and survival. The high prevalence of cognitive dysfunction in COPD may also help explain the insufficient adherence to therapeutic plans and strategies, thus worsening disease progression in people with COPD. However, the mechanisms underlying the impaired neuropathology and cognition in COPD remain largely unknown. In this review, we propose that the observed pulmonary oxidative burden and inflammatory response of people with COPD 'spills over' into the systemic circulation, resulting in damage to the brain and leading to cognitive dysfunction. As such, drugs targeting the lungs and comorbidities concurrently represent an exciting and unique therapeutic opportunity to treat COPD and cognitive impairments, which may lead to the production of novel targets to prevent and reverse the debilitating and life-threatening effects of cognitive dysfunction in COPD.

Citation

Pharmacology & Therapeutics 2022; 233: 108017

Jornal Title

Pharmacology & Therapeutics

Link

https://ahro.austin.org.au/austinjspui/handle/1/27694

Subject

Chronic obstructive pulmonary disease

Cognitive dysfunction

Microglia

Neuroinflammation

Oxidative stress

Smoking

Title

Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease.

Type of document

Journal Article

Austin Health

Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease.

Files:

Author(s)	Dobric, Aleksandar De Luca, Simone N Spencer, Sarah J Bozinovski, Steven Saling, Michael M McDonald, Christine F Vlahos, Ross
Publication Date	2021-10-06
Abstract	Chronic obstructive pulmonary disease (COPD) is a major incurable global health burden and currently, the 3rd largest cause of death in the world with approximately 3.23 million deaths per year. Globally, the financial burden of COPD is approximately €82 billion per year and causes substantial morbidity and mortality. Importantly, much of the disease burden and health care utilisation in COPD is associated with the management of its comorbidities and viral and bacterial-induced acute exacerbations (AECOPD). Recent clinical studies have shown that cognitive dysfunction is present in up to 60% of people with COPD, with impairments in executive function, memory, and attention, impacting on important outcomes such as quality of life, hospitalisation and survival. The high prevalence of cognitive dysfunction in COPD may also help explain the insufficient adherence to therapeutic plans and strategies, thus worsening disease progression in people with COPD. However, the mechanisms underlying the impaired neuropathology and cognition in COPD remain largely unknown. In this review, we propose that the observed pulmonary oxidative burden and inflammatory response of people with COPD 'spills over' into the systemic circulation, resulting in damage to the brain and leading to cognitive dysfunction. As such, drugs targeting the lungs and comorbidities concurrently represent an exciting and unique therapeutic opportunity to treat COPD and cognitive impairments, which may lead to the production of novel targets to prevent and reverse the debilitating and life-threatening effects of cognitive dysfunction in COPD.
Citation	Pharmacology & Therapeutics 2022; 233: 108017
Jornal Title	Pharmacology & Therapeutics
Link	https://ahro.austin.org.au/austinjspui/handle/1/27694
Subject	Chronic obstructive pulmonary disease Cognitive dysfunction Microglia Neuroinflammation Oxidative stress Smoking
Title	Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease.
Type of document	Journal Article